Recent Updates
Recently added Catalysts
MEDP Positive Sentiment

Medpace Holdings, Inc. Reports Third Quarter 2026 Results

Wednesday, October 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Medpace Holdings, Inc. reported its financial results for Q3 2026, showing an 8.5% increase in revenue to $716.0 million compared to $659.9 million in Q3 2025. The revenue growth was 8.6% on a constant currency basis. The company continues to demonstrate strong financial performance.

Market Sentiment Analysis

POSITIVE FACTORS

  • Revenue increased 8.5% to $716.0 million.
  • Constant currency revenue growth of 8.6% year-over-year.
  • Strong financial performance compared to the previous year.

Full Press Release Details

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2026. Third Quarter 2026 Financial Results Revenue for the three months ended September 30, 2026 increased 8.5% to $716.0 million, compared to $659.9 million for the comparable prior-year period. On a constant currency basis, revenue for the third quarter of 2026 increased 8.6% compared to the third quarter of 2025. Backlog as of September 30

Frequently Asked Questions

What was Medpace's revenue for Q3 2026?

Medpace reported revenue of $716.0 million for Q3 2026.

How much did revenue increase compared to Q3 2025?

Revenue increased by 8.5% compared to Q3 2025.

What was the constant currency revenue growth?

The constant currency revenue growth was 8.6% year-over-year.

When did Medpace announce its Q3 2026 results?

Medpace announced its Q3 2026 results on September 30, 2026.

ShareAdd on Google
Tags: MEDP Medpace financial results Q3 2026 revenue growth Cincinnati
Last updated: Oct 21, 2026

Biotech snapshot

Cash runway
$503M liquidity · $0M/mo burn
Low dilution risk